In two experiments, MEG was recorded during a picture naming task where the prime trials were designed to replicate previously reported combinatory effects and the target trials to test whether those combinatory effects could be primed.
First, we calculated accuracy for target present and target absent trials to test whether the radiologists could detect a mass at these durations.
Further studies will be required to demonstrate direct association of MeCP2 with HDACs at target genes and to test whether HDAC subtype binding to MeCP2 changes during development and in heart failure.
The rice mature mRNAs were used for target prediction in order to test whether these phased sRNAs could cleave targets in the cytoplasm.
As such a low number of targets was unexpected, we analyzed the individual read counts of candidate target genes in order to test whether these genes were missed in either treatment because they are synergistically regulated (supplementary material Fig. S3B).
As an alternative to expression breadth, we also incorporated data on tissue-specific expression profiles for each of the drug targets in our analysis to test whether quantitative tissue-specific expression changes the model relative to using a categorical expression breadth predictor.
Response 2: To validate that the effects of cavin-3 siRNA treatment were due to loss of cavin-3 as opposed to off-target effects, we chose to test whether loss of cavin-3 had similar effects in different model systems in which loss of cavin-3 resulted from different means: the MEF model uses a genetic knockout of the cavin-3 locus and the H1299 model is an epigenetic hypomorph of cavin-3.
In addition, we aimed to test whether target location would be classified with higher accuracy for category-level vs. exemplar-level non-human target faces, as suggested by the behavioural results, or vice-versa, as suggested by the ERP results.
Multiple validation cohorts were independently studied to test whether target indices were related to pathological response to neoadjuvant chemotherapy (GSE21094 (T/FAC), GSE22513 (T), GSE25055 & GSE25065 (AT).
The importance of frataxin for normal mitochondrial function makes it a possible target of PGC1A, prompting us to test whether PGC1A manipulation can affect frataxin levels.
